The paradigmatic hospital supply company of the 1980s was American Hospital Supply Corp., which was able to leverage strong relationships with customers and an efficient distribution system into a dominant position in the medical/surgical market. But for companies who tried to emulate AHSC, the leap from manufacturer to distributor proved difficult to make; moreover, customers themselves were willing to grant favored status to only a few such suppliers. In the 1990s, a new model of successful hospital supplier emerged: supplier as dealmaker, with an implicit faith in the value of technology and capable of putting together broad platforms. And in its own way, Tyco has helped to shape that model.
by David Cassak
On Mother's Day weekend of 1992, Richard Gilleland got a telephone call. Gilleland was at the time CEO of The...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
